Synthesis and Activity Evaluation of Nasopharyngeal Carcinoma Inhibitors Based on 6-(Pyrimidin-4-yl)-1H-indazole

Chemistry & Biodiversity
Bohong LiaoZhibo Zhu

Abstract

Human nasopharyngeal carcinoma is a common head and neck malignancy with high incidence in Southeast Asia and Southern China. It is necessary to develop safe, effective and inexpensive anticancer agents to improve the therapeutics of patients with nasopharyngeal carcinoma. A series of small molecular compounds based on 6-(pyrimidin-4-yl)-1H-indazole were synthesized and evaluated for antiproliferative activities against human nasopharyngeal carcinoma cell lines SUNE1. Compounds 6b, 6c, 6e and 6l showed potent antiproliferative activities similar to positive control drug cisplatin in vitro with lower nephrotoxicity than it. N-[4-(1H-Indazol-6-yl)pyrimidin-2-yl]benzene-1,3-diamine (6l) was selected for further study. It was found that 6l induced mitochondria-mediated apoptosis and G2 /M phase arrest in SUNE1 cells. Furthermore, compound 6l at 10 mg/kg can suppress the growth of an implanted SUNE1 xenograft with a TGI% (tumor growth inhibition) value of 50 % and did not cause serious side effects in BALB/c nude mice. This study suggests that 6-(pyrimidin-4-yl)-1H-indazole derivatives are a series of small molecule compounds with anti-nasopharyngeal carcinoma activities.

References

Oct 28, 2005·Mini Reviews in Medicinal Chemistry·Hugo CerecettoCarmen Ochoa de Ocáriz
Feb 3, 2009·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Feng JiangSanford A Stass
Mar 12, 2009·Molecular Cancer Research : MCR·Feng JiangRuth L Katz
Nov 23, 2010·The Biochemical Journal·Ayaz NajafovDario R Alessi
Feb 24, 2011·Journal of Medicinal Chemistry·Jesús R MedinaJeffrey M Axten
Feb 24, 2011·Journal of Medicinal Chemistry·Alexandra E GouldKatherine M Galvin
Jan 17, 2012·ACS Medicinal Chemistry Letters·Alexis MollardDavid J Bearss
Mar 13, 2014·International Journal of Cancer. Journal International Du Cancer·Josephine Mun Yee KoMaria Li Lung
Nov 11, 2010·ACS Medicinal Chemistry Letters·Jesús R MedinaJeffrey M Axten
Jul 12, 2014·Bioorganic & Medicinal Chemistry·Nathan J O'BrienBelinda M Abbott
Oct 10, 2015·European Journal of Medicinal Chemistry·Yuanyuan ShanMaoyi Wang
Feb 2, 2016·Cancer Letters·Ling-Ling TangWei-Hua Jia
Feb 23, 2017·Journal of Medicinal Chemistry·Stefano TomassiDaniel Rauh
May 10, 2017·Indian Journal of Cancer·S G LaskarJ P Agarwal
Jul 9, 2017·Bioorganic & Medicinal Chemistry Letters·Jing CuiYingxia Li
Oct 11, 2017·European Journal of Medicinal Chemistry·Lingfeng ChenGuang Liang
Feb 24, 2018·Bioorganic & Medicinal Chemistry·Bence SzilágyiGyörgy M Keserű
Jan 5, 2019·Physical Review Letters·D AdeyUNKNOWN Daya Bay Collaboration
Apr 2, 2019·Physical Review Letters·M AblikimUNKNOWN BESIII Collaboration

❮ Previous
Next ❯

Citations

Nov 27, 2020·Current Topics in Medicinal Chemistry·Congshan ShangGuoyan Cui

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.